Kane Biotech Inc V.KNE

New Press Release - Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health

Transaction will strengthen balance sheet and refocus company WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for the sale of its entire interest...read article.

[RoyMax123]

That's an good deal but nothing more, they will have enough cash for about 2 or 3 quarter. They keep the dev which will get them a bit a revenue, now let hope that they will finnaly launch the full revyve production soon.

[francoisl13]

Agree with you, it is a good/fair deal. The fact that they've paid Pivot Financials is a very good news. Now the interesting part of the story starts; 1. Revyve sales in the USa as well as approval in South America; 2. Revyve production going up; 3. Acne trial in Florida; 4. DispersinB phase 1 trial to start sometimes this year; 5. Revyve spray device FDA approval before year end Still a lot

[francoisl13]

STEM Animal was sold to Dechra Pharmaceuticals. An interesting point to note is that Kane/Animalcare and Dechra will jointly developed new products for the animal health market. Link to Animalcare press release Based on the Animalcare press release, that provides a little more information on the future relationship between the three companies, I think that the deal is a pretty good one -- better

[MirrorWorldMan]

Marc wanted a little financial breathing room and the amount is solid.  Paying off the high interest loan is smart and hopefully we can accelerate some revenues as everyone says rather than take another loan, the company is expensive to operate.  The repayment Helps our credit rating for sure.  As an aside, this transaction I reaized may help explain the departures of the executives